Novartis licenses Xencor's cancer immunotherapy candidates, XmAb technology
Xencor Inc. and Novartis Institutes for BioMedical Research Inc. will jointly collaborate on the development of bispecific antibodies as cancer immunotherapeutics, using Xencor's XmAb antibody engineering platform.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.